Scancell Holdings plc

For the 6 months ended 31 October 2025, Scancell reported no revenues. Research and development expenses were $6.2 million, administrative expenses were GBP 2.7 million, operating loss was GBP 8.9 million, profit on finance and other income was GBP 2.1 million, tax credit was GBP 1.1 million, and net loss was GBP 5.7 million. Cash at period end was GBP 8.6 million, including a GBP 3 million R&D tax credit received in the period. Management said cash runway remains in line with prior guidance into the second half of 2026, beyond key development milestones, and that iSCIB1+ could reach commercialization in the second half of 2029 if development proceeds as planned. They also said there are up to $630 million in further Genmab milestone payments tied to partnered antibody assets, plus low single-digit royalties and commercial sales on each antibody license.

Phil L’Huillier’s tone was strongly optimistic and validation-focused. He argued that iSCIB1+ now has best-in-class potential in first-line unresectable melanoma, citing durable clinical activity, a differentiated mechanism, and FDA backing of the Phase III design. He repeatedly framed the program as a large commercial opportunity, stressed the platform’s broader utility beyond melanoma, and said Scancell is pursuing both partnering and a build-to-commercialize strategy.

Sath Nirmalananthan emphasized cost discipline and runway management. He cited $6.2 million of R&D spend, GBP 2.7 million of administrative expenses, and GBP 8.6 million of cash at period end, noting the cash balance was boosted by a GBP 3 million R&D tax credit receipt. He said runway extends into the second half of 2026 beyond key milestones, but also highlighted upside from possible SC129 milestones this calendar year, Genmab milestones, discretionary spend control, and active partnering/financing discussions.

Analysts focused on geography in the Phase III stratification, the timing and impact of breakthrough designation, the rationale for partnering versus going alone, and the financing/dilution outlook. Management said they have looked closely at HLA types across geographies and do not expect major differences, that breakthrough designation should take roughly 2-3 months and would increase FDA interaction, and that the company is actively evaluating both partnering and a go-alone path. They also said the Phase III is double-blinded, so there will be no efficacy updates during the study; the main milestones investors can track will be recruitment and execution.